Susquehanna International Group
XENE icon

Susquehanna International Group’s Xenon Pharmaceuticals XENE Stock Holding History

Susquehanna International Group’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$61.1M Buy
1,050,900
+1,001,900
+2,045% +$46.2M 0.01% 1140
2025
Q4 		$2.2M Sell
49,000
-38,900
-44% -$1.63M ﹤0.01% 5456
2025
Q3 		$3.53M Buy
87,900
+2,600
+3% +$91.6K ﹤0.01% 4674
2025
Q2 		$2.67M Buy
+85,300
New +$2.78M ﹤0.01% 5197
2024
Q3 		– Sell
-28,300
Closed -$1.1M – 13178
2024
Q2 		$1.1M Sell
28,300
-4,900
-15% -$196K ﹤0.01% 6351
2024
Q1 		$1.43M Sell
33,200
-2,500
-7% -$115K ﹤0.01% 6115
2023
Q4 		$1.64M Buy
35,700
+3,100
+10% +$110K ﹤0.01% 5777
2023
Q3 		$1.11M Sell
32,600
-3,200
-9% -$120K ﹤0.01% 6393
2023
Q2 		$1.38M Buy
+35,800
New +$1.42M ﹤0.01% 5952
2023
Q1 		– Sell
-10,700
Closed -$422K – 13602
2022
Q4 		$422K Sell
10,700
-15,000
-58% -$546K ﹤0.01% 8293
2022
Q3 		$928K Sell
25,700
-23,000
-47% -$827K ﹤0.01% 6819
2022
Q2 		$1.48M Sell
48,700
-16,800
-26% -$508K ﹤0.01% 5563
2022
Q1 		$2M Sell
65,500
-14,100
-18% -$422K ﹤0.01% 5474
2021
Q4 		$2.49M Sell
79,600
-91,800
-54% -$2.74M ﹤0.01% 5011
2021
Q3 		$2.62M Buy
+171,400
New +$2.98M ﹤0.01% 5250

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Susquehanna International Group's XENE Position: Q1 2026 in Review

Susquehanna International Group increased its Xenon Pharmaceuticals (XENE) stake by 2,029% in Q1 2026, buying an estimated $7.78M and bringing the position to 177,137 shares worth $10.3M. The position accounts for ﹤0.01% of the portfolio, ranked #3070.

Susquehanna International Group first reported a position in XENE in Q2 2017 and has held it in 15 quarters since. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • Susquehanna International Group held 177,137 shares of Xenon Pharmaceuticals worth $10.3M as of Q1 2026.
  • Susquehanna International Group bought 168,818 Xenon Pharmaceuticals shares in Q1 2026, an estimated $7.78M.
  • Xenon Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #3070 holding.
  • Susquehanna International Group first reported a position in Xenon Pharmaceuticals in Q2 2017 and has held it in 15 quarters since.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.